Carillon Tower Advisers’s Amicus Therapeutics FOLD Stock Holding History

Carillon Tower Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$41.3M	Sell	1,786,637 -168,837	-9%	-$3.45M	0.25%	124
2020 Q3	$27.6M	Buy	1,955,474 +96,154	+5%	+$1.4M	0.37%	86
2020 Q2	$28M	Hold	1,859,320	–	–	0.22%	147
2020 Q1	$16.5M	Hold	1,859,320	–	–	0.16%	200
2019 Q4	$18.1M	Hold	1,859,320	–	–	0.12%	270
2019 Q3	$14.9M	Hold	1,859,320	–	–	0.1%	286
2019 Q2	$23.2M	Hold	1,859,320	–	–	0.16%	228
2019 Q1	$25.3M	Hold	1,859,320	–	–	0.18%	211
2018 Q4	$17.8M	Hold	1,859,320	–	–	0.15%	230
2018 Q3	$22.5M	Hold	1,859,320	–	–	0.16%	217
2018 Q2	$29M	Hold	1,859,320	–	–	0.23%	158
2018 Q1	$26.3M	Hold	1,859,320	–	–	0.2%	171
2017 Q4	$26.8M	Buy	+1,859,320	New	+$25.5M	0.28%	142

Other funds holding FOLD

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Carillon Tower Advisers's FOLD Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Amicus Therapeutics (FOLD) stake by 8.6% in Q4 2020, selling an estimated $3.45M and leaving 1,786,637 shares worth $41.3M. The position accounts for 0.25% of the portfolio, ranked #124.

Carillon Tower Advisers first reported a position in FOLD in Q4 2017 and has held it in 13 quarters since. 273 funds tracked by Wall St. Rank hold FOLD as of Q4 2020.

Carillon Tower Advisers held 1,786,637 shares of Amicus Therapeutics worth $41.3M as of Q4 2020.
Carillon Tower Advisers sold 168,837 Amicus Therapeutics shares in Q4 2020, an estimated $3.45M.
Amicus Therapeutics made up 0.25% of Carillon Tower Advisers's portfolio in Q4 2020, its #124 holding.
Carillon Tower Advisers first reported a position in Amicus Therapeutics in Q4 2017 and has held it in 13 quarters since.
273 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.